Rheumatoid arthritis: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• JAK 9
• TNF 9
• STAT3 0
• IL-6 2
• PI3K 0
• NLRP3 0
• CD19 17
• MAPK 0
• HIF-1 0
• NRF2 0
• mTOR 0
• IL-17 0
• AKT 0
• STING 0
• RANKL 0
• PPAR 0
• COX-2 0
• IL-1 0
• TLR4 0
• CD20 2
• TP53 0
• ERK 0
• PD-1 1
• SIRT1 0
• BCMA 7
• GLP-1 0
• MMP-9 0
• CTLA-4 1
• CTNNB1 0
• GPX4 0
• JNK 0
• SGLT2 1
• VEGF 1
• CD40 0
• HMGB1 0
• AMPK 0
• APOE 0
• AQP4 0
• CCR5 0
• FGFR 0
• IL-15 1
• METTL3 0
• PKM2 0
• TYK2 0
• CD38 1
• CGRP 0
• CXCR4 0
• IDO1 0
• PD-L1 0
• TIGIT 0
• BTK 0
• CD47 0
• EGFR 0
• HDAC 0
• IDH 0
• IL-23 0
• IL-4 0
• KEAP1 0
• MEK 0
• MYC 0

19 of 19+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  HARPNET – Harnessing Resolution Pharmacology for Next-Generation Therapeutics

  Queen Mary University of London· London, United Kingdom· EU contribution €4,793,228· until Sept 2030· 8 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  BSSL TARGETING THERAPY TOWARDS NON-IMMUNOSUPPRESSIVE RA TREATMENT (SOL-116 - BEYOND)

  Lipum Ab· Umea, Sweden· EU contribution €7,995,375· until Jun 2029· 3 countries

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  PRECISION-RA: Precision Immunotherapy for Rheumatoid Arthritis

  University of Bristol· Bristol, United Kingdom· EU contribution €150,000· until Nov 2027

• European Commission (Horizon Europe) · HORIZON-ERC

  Advancing NANOmedicines to rewire tumoral MYeloid cells for next-generation cancer immunotherapies (My-NANO)

  Universiteit Gent· Gent, Belgium· EU contribution €2,499,750· until Apr 2031

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Development of Armored targeted CAR-T cells for immune reset of T cell-mediated autoimmune diseases (iCARUS)

  Weizmann Institute of Science· Rehovot, Israel· EU contribution €150,000· until Sept 2027

  The disease is named only in the funder's project summary, not in the title.

5 of 35 running projects, newest first. Listed amounts together: €169.1m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  CD40L Antagonism in Rheumatoid Arthritis (RA)

  NCT05306353· National Institute of Allergy and Infectious Diseases (NIAID)· Updated 20 Jul 2026

  “The study is being closed early due to insufficient participant enrollment across study sites.”Registry text, quoted unchanged. Source

• Terminated

  Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RA

  NCT05246280· Navidea Biopharmaceuticals· Updated 23 Jan 2025

  “Sponsor Decision”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)

  NCT07137598· Hoffmann-La Roche· Source

• Discontinuation of Disease-modifying Anti-rheumatic Drugs (DMARDs) in Rheumatoid Arthritis Patients Also Using TNF Inhibitors

  NCT07802678· Sint Maartenskliniek· Source

• Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis

  NCT05814627· AbbVie· Source

• CD40L Antagonism in Rheumatoid Arthritis (RA)

  NCT05306353· National Institute of Allergy and Infectious Diseases (NIAID)· Source

• A Study of Baricitinib in Participants With Rheumatoid Arthritis

  NCT04086745· Eli Lilly and Company· Source

• Effect of Proactive Therapeutic Drug Monitoring on Maintenance of Sustained Disease Control in Adults With Rheumatoid Arthritis on a Subcutaneous TNF Inhibitor: The Rheumatoid Arthritis Therapeutic DRUg Monitoring Trial (RA-DRUM)

  NCT06440629· Diakonhjemmet Hospital· Source

• A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis

  NCT03915964· Eli Lilly and Company· Source

• Major Adverse Cardiovascular Events (MACE) in Rheumatoid Arthritis Patient With Moderate to Severe Disease Activity Treated With Tofacitinib and Statins vs TNF Inhibitors: TOFSTAT CLINICAL TRIAL

  NCT07554820· Shaikh Zayed Hospital, Lahore· Source

• COVID-19 VaccinE Response in Rheumatology Patients

  NCT05080218· Jeffrey Curtis· Source

• Nonsurgical Periodontal Treatment Combined With Anti-TNF-α in Patients With Rheumatoid Arthritis and Periodontitis

  NCT06818045· Hatice Yemenoğlu· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 43
• Organoids 3
• Mendelian Randomization Analysis 97
• CRISPR-Cas Systems 1
• Gene Expression Profiling 121
• Sequence Analysis, RNA 17
• Exome Sequencing 2
• Proteomics 52
• Metabolomics 45
• Mass Spectrometry 7
• Flow Cytometry 33
• Immunohistochemistry 18
• Liquid Biopsy 1
• Xenograft Model Antitumor Assays 2
• Positron-Emission Tomography 5
• Magnetic Resonance Imaging 58
• Machine Learning 87
• Deep Learning 9
• Cohort Studies 160
• Genome-Wide Association Study 113

• Integrative analysis reveals shared biomarkers and pathways in osteoporosis and rheumatoid arthritis using machine learning and single-cell sequencing.

  PLoS One, Nov 2026

• Cell DiffErential Expression by Pooling (CellDEEP) highlights issues in differential gene expression in scRNA-seq.

  NAR Genom Bioinform, Oct 2026

• Spatial multiomics identifies rheumatoid arthritis synovial niches and de-novo laminar histological patterns of fibroblasts subtypes.

  Front Immunol, Oct 2026

• Integrated Transcriptomic and Single-Cell Analysis Reveals Shared Macrophage-Associated Inflammatory Signatures in MASLD/NAFLD and Rheumatoid Arthritis.

  Int J Mol Sci, Oct 2026

• Single-cell Transcriptomics in Autoimmune Diseases: Mechanistic Insights, Cross-disease Convergence, and Translational Challenges in Rheumatoid Arthritis, Systemic Lupus Erythematosus, Type 1 Diabetes, and Multiple Sclerosis.

  Clin Rev Allergy Immunol, Oct 2026

• Donor-aware integrative single-cell analysis distinguishes consistent memory B-cell programmes from donor-sensitive state boundaries in untreated rheumatoid arthritis.

  Funct Integr Genomics, Oct 2026

• Single-cell mass cytometry cartography highlights systemic lupus erythematosus and Sjögren's disease immune differences.

  Front Immunol, Oct 2026

• Mendelian randomization and single-cell transcriptomics prioritize CD7 and LAPTM5 in primary Sjögren's disease: an integrative multi-omics analysis.

  Clin Rheumatol, Sept 2026

• Stage-specific ROMO1 in rheumatoid arthritis: predictive immune insights into the MIF pathway and HLA-DR/IL2RA axis via integrated GWAS, transcriptomic, single-cell, and spatial profiling.

  Autoimmunity, Sept 2026

• Single-Cell and Spatial Omics Uncover Disease-Specific Synovial Landscapes in Rheumatoid and Psoriatic Arthritis.

  J Rheumatol, Sept 2026

See which targets of this disease your abstract mentions, and go to the people working on them.